Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention | Zendy

Ricky D. Turgeon | Zendy; Sheri L. Koshman | Zendy; Erik Youngson | Zendy; Bryan Har | Zendy; Stephen B. Wilton | Zendy; Matthew T. James | Zendy; Michelle M. Graham | Zendy

Open Access

Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Author(s) -

Ricky D. Turgeon,

Sheri L. Koshman,

Erik Youngson,

Bryan Har,

Stephen B. Wilton,

Matthew T. James,

Michelle M. Graham

Publication year - 2020

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2019.6447

Subject(s) - medicine , ticagrelor , clopidogrel , acute coronary syndrome , percutaneous coronary intervention , mace , conventional pci , cardiology , population , aspirin , myocardial infarction , environmental health

Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased bleeding and dyspnea.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research